Travere Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Travere Therapeutics

02/05/2025 04:44

Travere Therapeutics Inc TVTX.OQ reported a quarterly adjusted loss of 47 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.76.  The mean expectation of fifteen analysts for the quarter was for a loss of 54 cents per share. Wall Street expected results to range from -63 cents to -46 cents per share.

Revenue rose 97.5% to $81.73 million from a year ago; analysts expected $77.58 million.

Travere Therapeutics Inc's reported EPS for the quarter was a loss of 47 cents​.

The company reported a quarterly loss of $41.23 million.

Travere Therapeutics Inc shares had risen by 16.1% this quarter and gained 19.5% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 5.3% in the last three months.​

In the last 30 days, five analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Travere Therapeutics Inc is $30.00

This summary was machine generated from LSEG data May 2 at 03:43 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.54
-0.47
Beat
Dec. 31 2024
-0.56
-0.73
Missed
Sep. 30 2024
-0.68
-0.70
Missed
Jun. 30 2024
-0.86
-0.91
Missed